The use of oestrogens in the longer term is an area of considerable current
scientific and clinical debate. The extra-reproductive range of oestrogen
actions is broad, with these steroid hormones and their receptors (ERs) bei
ng intimately involved in the normal function of, inter alia, the adult fem
ale skeleton, the cardiovascular system and the brain. Desirable as the res
toration of normal circulating oestrogen may be after menopause, HRT use is
compromised by the engagement of the reproductive sites of breast and uter
us. This may cause concern to patient and physician alike due to the conseq
uent imposition of cyclical bleeding and risk of breast malignancy. In the
individual patient, therefore, a balance of risk against benefit has to be
struck so that the patient may be precisely advised of the type and duratio
n of oestrogen replacement which may be indicated in her own case. The adve
nt of selective oestrogen receptor modulation with its ability to delete ad
verse effects in breast and endometrium, is a substantial pharmacological a
nd clinical advance.